Previous close | 22.15 |
Open | 22.12 |
Bid | 22.14 x 0 |
Ask | 22.15 x 0 |
Day's range | 22.10 - 22.38 |
52-week range | 20.38 - 32.08 |
Volume | |
Avg. volume | 8,839,387 |
Market cap | 53.739B |
Beta (5Y monthly) | 0.62 |
PE ratio (TTM) | 29.52 |
EPS (TTM) | 0.75 |
Earnings date | 27 Aug 2024 - 02 Sept 2024 |
Forward dividend & yield | 0.42 (1.90%) |
Ex-dividend date | 09 Aug 2023 |
1y target est | 29.11 |
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly endanger health and cost lives, but it also perpetuates a vicious cycle of inequity. People living in the most vulnerable situations including pregnant women and children under 5 years of age continue to be disproportionately impacted.
The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximately US$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Pharma for a triple artemisinin combination drug (Artemether-Lumefantrine-Amodiaquine fixed-dose formulation) against malaria in Africa and Southeast Asia, to accelerate the development and commercialization of this new drug.
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).